Stockreport

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline [Yahoo! Finance]

Gyre Therapeutics, Inc.  (GYRE) 
PDF assets and a robust pipeline of degraders, targeting inflammatory diseases and cancers. Access to degrader-antibody conjugates (DACs) platform technology for future di [Read more]